Jessica Bibliowicz
Director at APO
Board
About Jessica Bibliowicz
Independent director since March 2022; Chair of the Audit Committee. Age 65; B.S. in Government from Cornell University. Former President/CEO and later Chairman of National Financial Partners (NFP), taking it public in 2003 and serving until its 2013 acquisition; prior senior roles at Prudential Mutual Funds and Smith Barney Mutual Funds. Designated an “audit committee financial expert.”
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| National Financial Partners (NFP) | President & CEO; Chairman | CEO from 1999; Chairman from 2003; served until acquisition in 2013 | Took NFP public in 2003; led through sale in 2013 |
| Prudential Mutual Funds | Senior management | Not disclosed | Financial services leadership |
| Smith Barney Mutual Funds | Senior management | Not disclosed | Financial services leadership |
| Apollo Asset Management (AAM) | Independent Director; Audit Committee Chair | Mar 2022 – Sep 2023 | Chaired AAM audit committee |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Prudential Insurance Funds | Board member | Not disclosed | Current board member |
| Sotheby’s | Director (public company until 2019) | Prior to 2019 | Served until it went private in 2019 |
| Weill Cornell Medicine | Board of Fellows, Chair | More than 15 years | Current Chair of Board of Fellows |
| Cornell University | Board of Trustees | Current | Trustee |
| New York-Presbyterian | Board of Trustees | Current | Trustee |
Board Governance
- Independence: Board determined Ms. Bibliowicz is independent under NYSE rules and AGM guidelines .
- Committee leadership: Audit Committee Chair; designated “audit committee financial expert” .
- Audit Committee activity: Eight meetings in 2024; oversight of financial reporting, internal controls, auditor independence, and risk; recommended inclusion of FY2024 audited statements and appointment of Deloitte for FY2025 .
- Board activity and attendance: Board held four meetings in 2024; each director attended at least 75% of Board/committee meetings; 14 directors attended the 2024 annual meeting; independent-only executive sessions are part of governance practices .
- Audit Committee composition (2024–2025): Jessica Bibliowicz (Chair), Marc Beilinson, Michael Ducey, A.B. Krongard, Pauline Richards; Brian Leach added March 1, 2025; all independent, financially literate, and each member (including Ms. Bibliowicz) deemed a financial expert .
Fixed Compensation
| Component | 2024 Amount | Notes |
|---|---|---|
| Fees Earned or Paid in Cash | $200,000 | Reported in 2024 Director Compensation Table |
| Stock Awards | $0 | No stock awards reported for 2024 |
| All Other Compensation | $0 | No other compensation reported for 2024 |
| Total | $200,000 | 2024 total compensation |
Program structure:
- Base annual cash retainer for independent directors: $150,000 .
- Additional annual fees: $100,000 for independent chair/lead independent director; $25,000 for committee chair; $25,000 for committee member; ad hoc committees may carry additional fixed fees .
- Cash retainers/fees paid quarterly in arrears; partial-year service prorated .
Performance Compensation
| Item | 2024 Grants | Vesting | Performance Metrics |
|---|---|---|---|
| Annual RSU awards (non-employee directors) | Not granted to Ms. Bibliowicz in 2024 ($0 stock awards) | Time-based RSUs; unvested director RSUs not entitled to dividends/dividend equivalents | No director performance targets disclosed; director equity is time-based, not tied to financial KPIs |
Program guidance:
- Welcome grant RSUs: $200,000 value ($250,000 for Lead Independent Chair); vest on or about July 1 of the year following grant; continuing independent directors may elect to defer receipt of shares for annual RSUs .
Other Directorships & Interlocks
| Company/Entity | Type | Role | Potential Interlock/Notes |
|---|---|---|---|
| Prudential Insurance Funds | Financial services/funds | Board member | Insurance/fund governance; Apollo has significant insurance operations via AHL, but AGM reports no related-person material interests since Jan 1, 2024 beyond disclosed items |
| Sotheby’s | Auction house (public until 2019) | Former Director | Historical; went private in 2019 |
| Weill Cornell Medicine | Non-profit | Board of Fellows Chair | Non-profit leadership |
| Cornell University | Academic | Trustee | Non-profit/academic governance |
| New York-Presbyterian | Non-profit | Trustee | Non-profit governance |
Related-party and conflicts oversight: AGM states that, to its knowledge, since Jan 1, 2024 no related person had a material interest in ongoing business transactions/relationships except as described; AGM maintains an insider trading policy prohibiting hedging/derivatives and short-selling by directors, with limited exceptions for certain senior leaders under specified conditions .
Expertise & Qualifications
- Audit/Accounting expertise; designated audit committee financial expert .
- Senior executive leadership (public company CEO/Chair); public board experience; financial literacy; regulatory/legal/compliance experience .
- Apollo business/industry familiarity and governance skill set per director skills matrix .
Equity Ownership
| Holder | Shares Beneficially Owned | % of Outstanding | Notes |
|---|---|---|---|
| Jessica Bibliowicz | 7,670 | <1% | As of April 1, 2025; outstanding shares: 570,432,275 |
| Pledging/Hedging (policy) | — | — | Directors prohibited from hedging/derivatives and short-selling; limited exceptions for certain senior leaders’ prepaid variable forwards/pledging under conditions; no pledge disclosed for Ms. Bibliowicz |
Governance Assessment
- Strengths for investor confidence: Independent director; Audit Committee Chair; “financial expert” designation; active committee engagement (8 Audit meetings in 2024); majority independent board with annual elections, majority vote/resignation policy, executive sessions, proxy access, clawbacks, and director ownership guidelines (5x base cash retainer) .
- Alignment: Director equity is time-based RSUs; stock ownership guidelines require meaningful shareholding (5x $150,000 base retainer), with under-five-year directors expected to reach compliance within five years—Ms. Bibliowicz is within that window (joined 2022) .
- Watch items: 2024 compensation shows cash-only ($200,000) and no stock awards; monitor future RSU grants and ownership progression toward guideline compliance for alignment signal. No related-party transactions involving her disclosed; firm-level policy mitigates hedging/derivatives risk .
Overall, Ms. Bibliowicz’s audit leadership, independence, and financial expertise support board effectiveness; continued tracking of her equity accumulation versus guidelines will inform skin-in-the-game alignment in coming years.